Cardiff Shares Pop After Lead Asset Data In KRAS-Mutated Colorectal Cancer
- Clinical-stage biotech Cardiff Oncology Inc announced new preclinical and clinical data from its lead program in KRAS-mutated metastatic colorectal carcinoma (mCRC) in a second-line setup.
- The data featured in a presentation at the European Society for Medical Oncology (ESMO) Congress 2022 included updated data and biomarker analyses from Phase 1b/2 trial for onvansertib plus chemotherapy FOLFIRI and cancer therapy bevacizumab.
- As of July 26 data cutoff, overall response rate (ORR) and median progression-free survival (mPFS) significantly surpassed those in historical control studies.
- In an analysis of clinical responses, the KRAS responder group had greater ORR and mPFS than non-responders.
- Another ESMO presentation discussed a comparison between KRAS responders and non-responders in CRDF’s Expanded Access Program, which included patients who were ineligible to participate in the Phase 1b/2 trial.
- As of August 5, EAP patients who had received colorectal cancer therapy irinotecan demonstrated clinical benefit in response to onvansertib plus FOLFIRI/bevacizumab.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.